Clinical trial
The Study to Evaluate the Performance and Safety of the Novasight Hybrid System Using Objective Performance Criteria
NCT04617899 is registered in ClinicalTrials.gov with CardioNavi MedTech (Wuhan) Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Study to Evaluate the Performance and Safety of the Novasight Hybrid System Using Objective Performance Criteria
- Lead sponsor
- CardioNavi MedTech (Wuhan) Co., Ltd.
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- March 17, 2021
- Completion date
- December 31, 2021
- Enrollment
- 120 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.